---
id: antimicrobials_mac-treatment_040
category: antimicrobials
tags: [antimicrobials, MAC, mycobacterium-avium-complex, azithromycin, NTM]
deck: Infectious Diseases
created: 2025-11-10
modified: 2025-11-10
---

## Mycobacterium avium Complex (MAC) Treatment

**Q:** What are the treatment regimens for MAC pulmonary disease and disseminated MAC, including duration and prophylaxis?

**A:**

**Standard Treatment Regimen:**
- **Azithromycin** (or clarithromycin) + **Rifampin** + **Ethambutol**

**Duration:**
- **12 months after sputum culture conversion** (negative cultures)
- Total often 15-18 months

**Treatment by Disease Type:**

| **Disease Type** | **Regimen** | **Frequency** | **Duration** |
|------------------|-------------|---------------|--------------|
| **Noncavitary nodular bronchiectatic** | Azithromycin 500 mg + Rifampin 600 mg + Ethambutol 25 mg/kg | **3x/week** (Mon-Wed-Fri) | 12 months post-conversion |
| **Cavitary or severe disease** | Azithromycin 250-500 mg + Rifampin 600 mg + Ethambutol 15 mg/kg | **Daily** | 12 months post-conversion |
| **Disseminated MAC (HIV)** | Azithromycin 500 mg + Rifampin 600 mg + Ethambutol 15 mg/kg | **Daily** | Until CD4 >100 x ≥6 months on ART |

**Prophylaxis (HIV Patients):**
- **Indication:** CD4 <50 cells/µL
- **Regimen:** Azithromycin **1200 mg once weekly**
- **Alternative:** Clarithromycin 500 mg BID
- **Discontinue when:** CD4 >100 cells/µL for ≥3 months on ART

**Treatment Outcomes:**
- Current cure rate: **~65%**
- Recurrence rate: **~40%** (high)

**Rifampin Controversy (2024):**
- Recent debate: Some argue rifampin adds minimal activity to MAC regimens
- Pharmacokinetic/pharmacodynamic data suggest limited benefit
- Guidelines still include rifampin, but role being questioned

**Alternative/Add-On Agents (for refractory disease):**
- **Amikacin** (inhaled or IV)
- **Clofazimine**
- **Fluoroquinolone** (moxifloxacin)
- **Linezolid**

**Mnemonic: "MAC needs ARE for a year after negative"**
- **M**AC
- **A**zithromycin
- **R**ifampin
- **E**thambutol
- **A** year = 12 months after culture conversion

**Clinical Pearls:**
- MAC is **NOT contagious** (unlike M. tuberculosis)
- Often seen in **older women** with bronchiectasis or immunosuppression
- **"Lady Windermere syndrome"** = MAC in thin older women who suppress cough
- Treatment prolonged and challenging (adherence issues)
- Consider **inhaled amikacin** (Arikayce) for refractory disease

**Monitoring:**
- **Monthly sputum cultures** until conversion
- **Ethambutol:** Monthly visual acuity and color vision
- **Rifampin:** LFTs, drug interactions
- **Azithromycin:** QTc monitoring (especially if on other QT-prolonging drugs)

**Media:** None

**Sources:** [Medscape MAC Treatment 2024], [PMC 2024 - 2-drug daily MAC regimen], [AAC 2023/PMC 2023 - Rifampicin role in MAC], [PMC 2020 - Intermittent azithromycin/ethambutol], [PMC 2018 - MAC treatment overview], [PMC 2024 - Rifampicin no role viewpoint]
